沛嘉醫療-B(09996.HK):2021年含增值税收入1.54億元 同比增長253.2%
格隆匯1月27日丨沛嘉醫療-B(09996.HK)發佈公吿,截至2021年12月31日止年度,集團含增值税收入約人民幣1.543億元,同比增長約253.2%;收入人民幣1.365億元,同比增長253.2%。
公吿表示,含增值税收入及收入增加主要由於:(i)第一代TAVR產品TaurusOne®及第二代可回收TAVR產品TaurusElite®的商業化;(ii)可解脱彈簧圈及其他現有神經介入產品(包括SacSpeed®球囊擴張導管)的銷售收入增加;及(iii)多款神經介入新產品(包括Tethys®中間導管及Jasper®SS可電解脱彈簧圈)的商業化。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.